This Drug Pricing Scheme Could Be Making Your Medicine More Expensive
Biosimilars that are as safe and effective as expensive brand-name biologics could significantly reduce drug prices and healthcare spending, but only if they win support from insurers. Unfortunately, drugmakers like Johnson & Johnson (NYSE: JNJ) may be employing tactics to keep that from happening.
In this episode of the Motley Fool's Industry Focus: Healthcare podcast, analyst Michael Douglass is joined by contributor Todd Campbell to dig into the details of a lawsuit recently filed against Johnson & Johnson by Pfizer (NYSE: PFE). In its claim, Pfizer accuses J&J of negotiating contracts with insurers that prevent coverage of Pfizer's biosimilar to Remicade, a top-selling autoimmune disease drug. Listen in to find out how this scheme could be increasing drug prices.
Also, the two weigh in on Axovant Sciences' (NASDAQ: AXON) disappointing setback in Alzheimer's disease and how its recent high-profile trial failure impacts patients and shareholders.
Source: Fool.com
Pfizer Inc. Aktie
Die Community bevorzugt klar Pfizer Inc. mit vielen Buy- und nur wenigen Sell-Einschätzungen.
Das Community-Kursziel von 41 € für Pfizer Inc. deutet auf eine deutliche Steigerung um mehr als 50% gegenüber dem aktuellen Kurs von 26.38 € hin.
